Profile data is unavailable for this security.
About the company
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
- Revenue in USD (TTM)166.88m
- Net income in USD-74.18m
- Incorporated2018
- Employees357.00
- LocationAnika Therapeutics Inc32 Wiggins AveBEDFORD 01730-2315United StatesUSA
- Phone+1 (781) 457-9000
- Fax+1 (781) 305-9720
- Websitehttps://anika.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Teknova Inc | 34.94m | -34.27m | 271.85m | 210.00 | -- | 2.64 | -- | 7.78 | -0.9295 | -0.9295 | 0.9167 | 1.93 | 0.2819 | 2.36 | 6.84 | 166,381.00 | -27.65 | -- | -32.36 | -- | 22.38 | -- | -98.08 | -- | 3.28 | -29.50 | 0.144 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Atlantic International Corp | 205.26m | -62.29m | 297.25m | 7.00 | -- | 11.68 | -- | 1.45 | -8.72 | -8.72 | 14.59 | 0.5222 | 2.91 | -- | 7.03 | 29,322,780.00 | -88.44 | -71.97 | -174.30 | -106.09 | 10.70 | 61.01 | -30.35 | -1,471.82 | -- | -1.33 | 0.7735 | -- | -100.00 | -- | -37.43 | -- | -- | -- |
| AngioDynamics, Inc. | 303.91m | -184.35m | 303.69m | 748.00 | -- | 1.48 | -- | 0.9993 | -4.57 | -4.57 | 7.56 | 5.08 | 0.7148 | 2.57 | 6.30 | 406,302.10 | -43.36 | -16.38 | -54.60 | -18.70 | 50.90 | 52.95 | -60.66 | -30.49 | 1.46 | -- | 0.00 | -- | -10.28 | 2.35 | -251.53 | -- | 13.09 | -- |
| OraSure Technologies, Inc. | 273.54m | 27.03m | 322.88m | 638.00 | 11.99 | 0.7582 | 8.10 | 1.18 | 0.3611 | 0.3611 | 3.68 | 5.71 | 0.5947 | 2.72 | 6.02 | 428,738.30 | 6.00 | 0.7238 | 6.53 | 0.8212 | 44.62 | 46.94 | 10.09 | 1.13 | 10.84 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Cerus Corp | 194.51m | -24.06m | 333.54m | 288.00 | -- | 6.73 | -- | 1.71 | -0.1319 | -0.1319 | 1.07 | 0.2673 | 1.01 | 1.98 | 8.40 | 675,371.50 | -12.56 | -25.99 | -19.03 | -40.62 | 60.79 | 61.90 | -12.41 | -35.81 | 1.83 | -1.51 | 0.6244 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Pulmonx Corp | 76.58m | -57.86m | 335.93m | 279.00 | -- | 3.32 | -- | 4.39 | -1.50 | -1.50 | 1.99 | 2.58 | 0.4188 | 1.21 | 7.65 | 274,491.00 | -31.64 | -26.27 | -35.08 | -28.97 | 74.19 | 71.95 | -75.56 | -93.76 | 7.92 | -- | 0.2688 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Sight Sciences Inc | 79.40m | -52.32m | 337.06m | 214.00 | -- | 3.30 | -- | 4.25 | -1.06 | -1.06 | 1.61 | 2.03 | 0.474 | 1.53 | 4.18 | 371,004.70 | -31.24 | -38.78 | -34.01 | -42.20 | 85.80 | 80.74 | -65.90 | -105.14 | 10.50 | -26.50 | 0.2494 | -- | 13.63 | 60.84 | 35.59 | -- | 6.77 | -- |
| Treace Medical Concepts Inc | 198.53m | -63.68m | 338.32m | 516.00 | -- | 3.02 | -- | 1.70 | -1.03 | -1.03 | 3.21 | 1.80 | 0.8347 | 1.14 | 7.52 | 384,753.90 | -26.77 | -- | -31.74 | -- | 80.67 | -- | -32.08 | -- | 2.93 | -- | 0.3216 | -- | 31.92 | -- | -15.68 | -- | -- | -- |
| Tactile Systems Technology Inc | 281.54m | 32.59m | 339.61m | 992.00 | 10.38 | 1.69 | 8.66 | 1.21 | 1.37 | 1.37 | 11.81 | 8.37 | 1.02 | 7.10 | 6.36 | 283,814.50 | 11.80 | 0.9015 | 13.87 | 1.09 | 50.63 | 49.10 | 11.58 | 0.8309 | 3.89 | -- | 0.1211 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Clearpoint Neuro Inc | 28.07m | -17.98m | 342.19m | 107.00 | -- | 10.65 | -- | 12.19 | -0.7062 | -0.7062 | 1.10 | 1.16 | 0.5602 | 1.31 | 8.95 | 262,327.10 | -35.89 | -34.75 | -46.51 | -39.67 | 59.85 | 64.75 | -64.06 | -76.91 | 2.31 | -- | 0.237 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Nano-X Imaging Ltd | 10.13m | -57.47m | 356.25m | 164.00 | -- | 2.03 | -- | 35.17 | -0.9974 | -0.9974 | 0.1755 | 2.99 | 0.0482 | -- | 6.89 | 61,756.10 | -27.33 | -30.98 | -29.96 | -35.10 | -81.80 | -- | -567.41 | -1,527.24 | 5.09 | -- | 0.0181 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| Anika Therapeutics Inc | 166.88m | -74.18m | 377.32m | 357.00 | -- | 1.80 | -- | 2.26 | -5.06 | -5.06 | 11.35 | 14.17 | 0.5642 | 1.34 | 4.73 | 467,451.00 | -25.08 | -5.41 | -27.37 | -5.87 | 62.16 | 60.70 | -44.45 | -12.60 | 3.96 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Butterfly Network Inc | 71.08m | -108.96m | 380.51m | 225.00 | -- | 1.96 | -- | 5.35 | -0.5236 | -0.5236 | 0.3407 | 0.9144 | 0.2229 | 0.6382 | 4.19 | 315,911.10 | -34.17 | -- | -39.55 | -- | 27.73 | -- | -153.29 | -- | 3.20 | -- | 0.00 | -- | -10.21 | -- | 20.76 | -- | -- | -- |
| MaxCyte Inc | 45.44m | -35.43m | 431.20m | 143.00 | -- | 1.94 | -- | 9.49 | -0.3408 | -0.3408 | 0.437 | 2.11 | 0.1739 | 0.4741 | 7.46 | 317,762.90 | -13.56 | -13.18 | -14.25 | -14.33 | 88.43 | 88.79 | -77.97 | -62.96 | 13.40 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Varex Imaging Corp | 832.70m | 34.20m | 441.31m | 2.30k | 23.59 | 0.7586 | 6.49 | 0.530 | 0.4574 | 0.4574 | 16.46 | 14.22 | 0.6758 | 1.95 | 5.28 | 346,958.30 | 2.82 | 0.9913 | 3.33 | 1.18 | 32.16 | 31.70 | 4.17 | 1.36 | 1.89 | 2.00 | 0.4271 | -- | 3.96 | 2.93 | 59.08 | 18.88 | 0.2924 | -- |
| ZimVie Inc | 453.38m | -54.86m | 456.31m | 2.60k | -- | 1.16 | -- | 1.01 | -2.04 | -13.27 | 16.84 | 14.29 | 0.3858 | 1.12 | 3.80 | 174,378.50 | -4.67 | -- | -5.43 | -- | 63.11 | 65.51 | -12.10 | -8.73 | 1.43 | -0.3884 | 0.3737 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
Data as of Sep 20 2024. Currency figures normalised to Anika Therapeutics Inc's reporting currency: US Dollar USD
56.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Trigran Investments, Inc.as of 30 Jun 2024 | 2.14m | 14.44% |
| Caligan Partners LPas of 30 Jun 2024 | 1.44m | 9.71% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.07m | 7.25% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 773.92k | 5.23% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 711.30k | 4.81% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 598.23k | 4.04% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 501.95k | 3.39% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 442.94k | 2.99% |
| BlackRock Financial Management, Inc.as of 30 Jun 2024 | 366.11k | 2.47% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 349.96k | 2.37% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
